AcquiSci has developed a platform medical device technology, called d-OSAB™, a treatment approach targeting a range of disorders that involve inflammation, such as ischemic brain stroke and chronic heart failure as well as a process for BioFluid purification, known as PathPure™.

Ischemic stroke was chosen as the first clinical indication because it is a huge unmet need, and its short clinical trial requirement compared to chronic heart failure. Further, the stroke problem is $50+ billion market in the US and EU.